Cushing's Syndrome Awareness

In this video playlist, Maria Fleseriu, MD, FACE, professor of medicine and neurological surgery, and Pituitary Center director of Oregon Health and Science University, Portland, discusses:

• the process of diagnosing Cushing’s syndrome, including screening, confirmation and localization;
• recurrence rates in Cushing’s disease, which “could be as high as 35% after pituitary surgery during long-term follow-up”;
• developments in the treatment of Cushing’s syndrome and Cushing’s disease, including the recent FDA approvals of osilodrostat (Isturisa, Recordati) and levoketoconazole (Recorlev, Xeris Biopharma);
• common comorbidities seen with Cushing’s syndrome, such as cardiovascular complications and diabetes; and
• the importance of increasing awareness of these conditions in the medical community.

References:

Fleseriu M, et al. Lancet Diabetes Endocrinol. 2019;doi:10.1016/S2213-8587(19)30313-4.

Fleseriu M, et al. Lancet Diabetes Endocrinol. 2021;doi:10.1016/S2213-8587(21)00235-7.

Gadelha M, et al. J Clin Endocrinol Metab. 2022;doi:10.1210/clinem/dgac178.

Pivonello R, et al. Front Endocrinol (Lausanne). 2022;doi:10.3389/fendo.2022.899616.